

About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.

Spherix Provides Independent Expertise in Seven Areas



Dermatology



Nephrology



Gastroenterology



Neurology



Rheumatology



Ophthalmology



This is a guide to the publications Spherix will produce in 2025. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications		
MARKET DYNAMI/	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.	
REALTIME DYNAMIX	A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.	
LAUNCH DYNAMI/	Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.	
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmasks real patient management patterns an uncovers the "why" behind treatment decisions.	
SPECIAL TOPIX	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.	

For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com



2025 Dermatology Publications



Atopic Dermatitis		
MARKET DYNAMI/	Atopic Dermatitis, US	
REALTIME DYNAMIX	Atopic Dermatitis, EU5Atopic Dermatitis, JP/ CH	
LAUNCH DYNAMI/	 Ebglyss (Eli Lilly) in Atopic Dermatitis, US Nemluvio (Galderma) in Atopic Dermatitis, US Vtama and Zoryve (Arcutis/ Dermavant) in Atopic Dermatitis, US 	
PATIENT CHART DYNAMIX	Atopic Dermatitis, US	

	Alopecia Areata
MARKET DYNAMI/	Alopecia Areata, US
LAUNCH DYNAMIX	 Leqselvi (SUN Pharma) in Alopecia Areata, US Litfulo (Pfizer) in Alopecia Areata, US

Hidradenitis Suppurativa		
MARKET DYNAMI/	Hidradenitis Suppurativa, US	
REALTIME DYNAMIX	Hidradenitis Suppurativa, EU5	
LAUNCH DYNAMI/	 Bimzelx (UCB) in Hidradenitis Suppurativa, US* Cosentyx (Novartis) in Hidradenitis Suppurativa, US 	

Derm	atolo	gy Relat	ed Respira	tory

MARKET	 Asthma, US
DYNAMIX	• Chronic Spontaneous Urticaria, US

Plaque Psoriasis		
REALTIME DYNAMI/	Plaque Psoriasis, USPlaque Psoriasis, EU5	
LAUNCH DYNAMIX	Bimzelx (UCB) in Plaque Psoriasis, US	
PATIENT CHART DYNAMI/	Plaque Psoriasis, US	
SPECIAL TOPIX	The Oral Opportunity in Plaque Psoriasis, US	

Other Dermatology Indications			
MARKET DYNAMI/	Prurigo Nodularis, USVitiligo, US		
LAUNCH DYNAMIX	 Dupixent (Sanofi/Regeneron) in Chronic Spontaneous Urticaria, US Dupixent (Sanofi/Regeneron) in Chronic Obstructive Pulmonary Disease, US Remibrutinib (Novartis) in Chronic Spontaneous Urticaria, US Nemluvio (Galderma) in Prurigo Nodularis, US 		
SPECIAL TOPI/	 Biologic Coordinators Across Dermatology, US Awareness and Expected Impact of IRA Changes in 2025 		

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
1	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



2025 Gastroenterology Publications



Eosinophilic Esophagitis MARKET DYNAMI. • Eosinophilic Esophagitis, US • Eosinophilic Esophagitis, EU5 LAUNCH DYNAMI. • Eohilia (Takeda) in Eosinophilic Esophagitis, US

Inflammatory Bowel Disease			
REALTIME DYNAMI/	 Crohn's Disease, US Crohn's Disease, EU5 Ulcerative Colitis, US Ulcerative Colitis, EU5 		
LAUNCH DYNAMIX	 Entyvio SC (Takeda) in Crohn's Disease, US Tremfya (Janssen) in Crohn's Disease, US* Omvoh (Eli Lilly) in Crohn's Disease, US* Entyvio SC (Takeda) in Ulcerative Colitis, US Omvoh (Eli Lilly) in Ulcerative Colitis, US Skyrizi (AbbVie) in Ulcerative Colitis, US Tremfya (Janssen) in Ulcerative Colitis, US Velsipity (Pfizer) in Ulcerative Colitis, US 		
PATIENT CHART DYNAMI/	 Inflammatory Bowel Disease New Starts, US Inflammatory Bowel Disease Switching, US Inflammatory Bowel Disease Switching, EU5 		

Metabolic Dysfunction-associated Steatotic Liver Disease / Metabolic Dysfunction-associated Steatohepatitis		
MARKET DYNAMI/	• MASLD/MASH, US	
LAUNCH DYNAMIX	Rezdiffra (Madrigal) in MASLD/MASH, US	
PATIENT CHART DYNAMI/	• MASLD/MASH, US	

Other Gastroenterology Indications		
MARKET DYNAMI/	 Celiac Disease, US Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US 	
REALTIME DYNAMIX	Irritable Bowel Syndrome, US	
LAUNCH DYNAMI/	 Iqirvo (Ipsen) in Primary Biliary Cholangitis, US Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US 	
SPECIAL TOPI/	 The Role of Primary Care in Gastroenterology, US Awareness and Expected Impact of IRA Changes in 2025 	

key	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



2025 Rheumatology Publications



Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

MARKET DYNAMI/	 Ankylosing Spondylitis & nr-AxSpA, US Ankylosing Spondylitis & nr-AxSpA, EU5
LAUNCH	 Bimzelx (UCB) in Ankylosing Spondylitis & nr-
DYNAMIX	AxSpA, US

Lupus		
MARKET DYNAMI/	 Systemic Lupus Erythematosus, US Systemic Lupus Erythematosus, EU5 Cutaneous Lupus Erythematosus, US 	
REALTIME DYNAMI/	Lupus Nephritis, USLupus Nephritis, EU5	
LAUNCH DYNAMI/	Gazyva (Genentech) in Lupus Nephritis, US*	
PATIENT CHART DYNAMI/	 Lupus Nephritis, US Moderate to Severe SLE, US Moderate to Severe SLE, EU5 	

	Psoriatic Arthritis
MARKET DYNAMI/	Psoriatic Arthritis, EU5
REALTIME DYNAMIX	Psoriatic Arthritis, US
LAUNCH DYNAMI/	 Bimzelx (UCB) in Psoriatic Arthritis, US Sotyktu (BMS) in Psoriatic Arthritis, US*
PATIENT CHART DYNAMIX	Psoriatic Arthritis, US

Other Rheumatology Indications		
MARKET DYNAMI⁄	 Dermatomyositis, US (2024) Giant Cell Arteritis, US (2024) Idiopathic Inflammatory Myopathy, US Polymyalgia Rheumatica, US (2024) Rheumatoid Arthritis, US Rheumatoid Arthritis, EU5 Sjogren's Syndrome, US Systemic Sclerosis, US Systemic Sclerosis, EU5 (2024) 	
LAUNCH DYNAMIX	 Hizentra (CSL) in Dermatomyositis, US* Rinvoq (AbbVie) in Giant Cell Arteritis, US* 	
SPECIAL TOPI/	 Cell Therapy in Rheumatology, US Feedback from ACR Convergence, US Interstitial Lung Disease in Rheumatology, US Awareness and Expected Impact of IRA Changes in 2025 	

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



Kidney Disease		
MARKET DYNAMI/	 Autosomal Dominant Polycystic Kidney Disease, US CKD& DKD, Cross-Specialty Perspective, US 	
REALTIME DYNAMI/	 Hyperkalemia, US Dialysis, US Dialysis, Renal Dietitians, US Dialysis, EU5 	
LAUNCH DYNAMI/	 Xphozah (Ardelyx) in Hyperphosphatemia, US Xphozah (Ardelyx) in Hyperphosphatemia, Renal Dietitians, US Jesduvroq (GSK) in Renal Anemia, US Vafseo (Akebia) in Renal Anemia, US OLC (Unicycive) in Hyperphosphatemia, US* 	
PATIENT CHART DYNAMIX	 Chronic Kidney Disease, Non-Dialysis, Nephrology, US Dialysis, US 	
SPECIAL TOPI.	 Hypertension in CKD, US Implications of the Dialysis Bundle (US) ASN Kidney Week Conference, US Buy and Bill in Nephrology Practices, US Awareness and Expected Impact of IRA Changes in 2025, US 	

Glomerular Diseases	
MARKET DYNAMI/	 Complement 3 Glomerulopathy, US Focal Segmental Glomerulosclerosis, US Membranous Nephropathy, US
REALTIME DYNAMIX	IgA Nephropathy, USIgA Nephropathy, EU5
LAUNCH DYNAMI/	 Fabhalta (Novartis) in IgAN, US Vanrafia (Novartis) in IgAN, US Sibeprenlimab (Otsuka) in IgAN, US* Fabhalta (Novartis) in C3G, US Empaveli (Apellis) in C3G, US*
PATIENT CHART DYNAMIX	 Complement 3 Glomerulopathy, US Focal Segmental Glomerulosclerosis, US IgA Nephropathy, US IgA Nephropathy, EU5 IgA Nephropathy, Japan IgA Nephropathy, China
PATIENT DYNAMI/	• IgA Nephropathy, US

	Lupus Nephritis
REALTIME DYNAMI/	Lupus Nephritis, USLupus Nephritis, EU5
PATIENT CHART DYNAMIX	• Lupus Nephritis, US

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



2025 Neurology Publications



	Alzheimer's Disease
MARKET DYNAMI/	 Alzheimer's Disease, US: Focus on Diagnostic Pathway (Q2) Alzheimer's Disease, US: Focus on Pipeline (Q4)
LAUNCH DYNAMIX	 Leqembi (Eisai/Biogen) in Alzheimer's Disease, US Kisunla (Eli Lilly) in Alzheimer's Disease, US
PATIENT CHART DYNAMI/	Alzheimer's Disease, US

Generalized Myasthenia Gravis			
REALTIME DYNAMI/	Generalized Myasthenia Gravis, USGeneralized Myasthenia Gravis, EU5		
LAUNCH DYNAMIX	 Biosimilar eculizumab in Generalized Myasthenia Gravis, US Imaavy in Generalized Myasthenia Gravis, US SC Biologics in Generalized Myasthenia Gravis, US Uplizna in Generalized Myasthenia Gravis, US* 		
PATIENT CHART DYNAMI/	General Myasthenia Gravis, US		

Migraine		
REALTIME DYNAMI/	Migraine, US	
LAUNCH DYNAMIX	Zavzpret (Pfizer) in Acute Migraine, US	

Multiple Sclerosis		
MARKET DYNAMI/	 Multiple Sclerosis, US: Focus on Current Market Landscape (Q1) Multiple Sclerosis, US: Focus on Pipeline Opportunities (Q3) 	
REALTIME DYNAMIX	Multiple Sclerosis, Canada	
LAUNCH DYNAMI/	Ocrevus Zunovo (Genentech) in Multiple Sclerosis, US	

Other Neurology Indications		
MARKET DYNAMI/	 Chronic Inflammatory Demyelinating Polyneuropathy, US Epilepsy, US Parkinson's Disease, US 	
SPECIAL TOPIX	Neurology Pipeline Opportunities, USPractice Dynamix in Neurology, US	

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas



2025 Ophthalmology Publications



Diabetic Macular Edema		
REALTIME DYNAMI/	Diabetic Macular Edema, US	
LAUNCH DYNAMIX	Pavblu in Diabetic Macular Edema, US	
PATIENT CHART DYNAMI/	Diabetic Macular Edema, US	
Neovascular Age-Related Macular Degeneration		

Neovascular Age-Related Macular Degeneration		
REALTIME DYNAMI/	Neovascular Age-Related Macular Degeneration, US	
LAUNCH DYNAMIX	 Pavblu in Neovascular Age-Related Macular Degeneration, US 	
PATIENT CHART DYNAMI/	Neovascular Age-Related Macular Degeneration, US	

Other Ophthalmology Indications		
MARKET DYNAMI/	 Geographic Atrophy, US Glaucoma, US Thyroid Eye Disease (TED), US 	
LAUNCH DYNAMIX	Pavblu in Diabetic Retinopathy, US	
SPECIAL TOPI/	 Gene Therapies in Retina, US Pipeline Opportunities in Ophthalmology, US 	

Key

MARKET DYNAMIX Yearly market overview of key indication

REALTIME DYNAMIX Quarterly (US) or semi-annual (EU5) indication updates

LAUNCH DYNAMIX Monthly benchmark of newly launched products

PATIENT CHART DYNAMIX Yearly review of large-scale patient chart audits

SPECIAL TOPIX Current events on specific interest areas

REALTIME

2025 Hematology Publications



Paroxysmal Nocturnal Hemoglobinuria MARKET DYNAMI • Paroxysmal Nocturnal Hemoglobinuria, EU5

Paroxysmal Nocturnal Hemoglobinuria LIS

DYNAMIX	r aroxysmar voctamar nemogropmana, os
PATIENT CHART DYNAMI/	Paroxysmal Nocturnal Hemoglobinuria, US

Blood Clotting Disorders	
MARKET DYNAMI/	Hemophilia, USHemophilia, EU5
LAUNCH DYNAMIX	 Hympavzi in Hemophilia A & B Alhemo in Hemophilia A & B Ofitlia in Hemophilia A & B

Sickle Cell Disease and Thalassemia		
MARKET DYNAMI/	Sickle Cell Disease, USThalassemia, US	
LAUNCH DYNAMIX	 Casgevy and Lyfgenia in Sickle Cell Disease and Beta-Thalassemia, US 	
PATIENT CHART DYNAMI/	Sickle Cell Disease, US Thalassemia. US	

Hemoglobinopathies -

Other Benign Hematology Indications		
MARKET	 Cold Agglutin Disease (CAD) Graft vs. Host Disease (GvHD) Thrombocytopenia (Including ITP and TTP) Warm Autoimmune Hemolytic Anemia	
DYNAMI/	(w-AIHA)	
SPECIAL	 Adoption and Impact of Gene Therapy in	
TOPIX	Hematology Multi-Specialty Approach to aHUS	

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas

Visit The Spherix Portal



